Nicole C. Goodwin

发表

Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.

Joseph P. Romano, N. C. Goodwin, J. Bertin, 2019, ACS medicinal chemistry letters.

Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

Alan G. E. Wilson, N. C. Goodwin, F. Mseeh, 2009, Journal of medicinal chemistry.

LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice

Alan G. E. Wilson, N. C. Goodwin, F. Mseeh, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.

Alan G. E. Wilson, N. C. Goodwin, F. Mseeh, 2017, Journal of medicinal chemistry.

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

Alan G. E. Wilson, N. C. Goodwin, F. Mseeh, 2012, Clinical pharmacology and therapeutics.

Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.

N. C. Goodwin, Giovanni Cianchetta, D. B. Rawlins, 2015, ACS medicinal chemistry letters.

Design and Characterization of 1,3-Dihydro-2H-benzo[d]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors.

P. Bamborough, R. Prinjha, P. Soden, 2023, ACS medicinal chemistry letters.

Biocatalysis in Medicinal Chemistry: Challenges to Access and Drivers for Adoption.

N. C. Goodwin, Timin Hadi, J. Morrison, 2019, ACS medicinal chemistry letters.

The first enantioselective organocatalytic Mukaiyama-Michael reaction: a direct method for the synthesis of enantioenriched gamma-butenolide architecture.

Sean P. Brown, N. C. Goodwin, D. MacMillan, 2003, Journal of the American Chemical Society.

Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.

Y. Liu, Nita Patel, David B Rawlins, 2015, ACS medicinal chemistry letters.

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2

Alan G. E. Wilson, N. C. Goodwin, F. Mseeh, 2015, Pharmacology research & perspectives.